remdesivir - Profile

What are the generic sources for remdesivir and what is the scope of patent protection?

Remdesivir is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Remdesivir has three hundred and forty-four patent family members in forty-nine countries.

Summary for remdesivir

International Patents:	344
US Patents:	16
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for remdesivir

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for remdesivir

Constraining patent/regulatory exclusivity:

11,492,353*PED

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for REMDESIVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VEKLURY	Powder for Injection	remdesivir	100 mg/vial	214787	1	2025-04-22

US Patents and Regulatory Information for remdesivir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	11,492,353*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	11,491,169*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	11,903,953*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	11,007,208*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	11,382,926*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	9,949,994*PED				Y
Gilead Sciences Inc	VEKLURY	remdesivir	POWDER;INTRAVENOUS	214787-001	Oct 22, 2020		RX	Yes	Yes	10,675,296*PED				Y

EU/EMA Drug Approvals for remdesivir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Veklury	remdesivir	EMEA/H/C/005622Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	Authorised	no	no	no	2020-07-03

International Patents for remdesivir

Country	Patent Number	Title	Estimated Expiration
Peru	20171155	METODOS Y COMPUESTOS PARA TRATAR INFECCIONES VIRALES POR PARAMYXOVIRIDAE
Japan	6671424
Hungary	E039231
Eurasian Patent Organization	201071128
Lithuania	PA2020539
Hungary	E057928
Mexico	2018003161	METODOS PARA TRATAR INFECCIONES POR VIRUS ARENAVIRIDAE Y CORONAVIRIDAE. (METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS.)

Supplementary Protection Certificates for remdesivir

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2937350	CR 2020 00060	Denmark		PRODUCT NAME: REMDESIVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1459 20200703
2595980	132020000000176	Italy		PRODUCT NAME: REMDESIVIR O SALE O ESTERE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO(VEKLURY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1459, 20200703
2595980	202040053	Slovenia		PRODUCT NAME: REMDESIVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER; NATIONAL AUTHORISATION NUMBER: EU/1/20/1459; DATE OF NATIONAL AUTHORISATION: 20200703; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2937350	PA2020539,C2937350	Lithuania		PRODUCT NAME: REMDESIVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1459 20200703
2937350	CA 2020 00060	Denmark		PRODUCT NAME: REMDESIVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/20/1459 20200703
2937350	PA2020539	Lithuania		PRODUCT NAME: REMDESIVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1459 20200703
2595980	C02595980/01	Switzerland		PRODUCT NAME: REMDESIVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68043 25.11.2020

Remdesivir: Investment Dynamics, Market Landscape, and Financial Outlook

Last updated: February 3, 2026

---

Summary

Remdesivir (brand name Veklury), developed by Gilead Sciences, is an antiviral originally designed for Ebola and later repurposed for COVID-19 treatment. Regulatory approvals and market dynamics significantly impacted its commercial trajectory. While initially positioned as a frontline COVID-19 therapy, subsequent clinical trials and evolving treatment protocols have influenced its market penetration and financial performance. This report analyzes current investment scenarios, market forces, and future financial prospects for Remdesivir, incorporating current regulatory and competitive contexts and projecting industry trends.

---

What is the Current Investment Landscape for Remdesivir?

Aspect	Details
Market Value (2022-2023)	Estimated at USD 8.2 billion in sales globally (Source: EvaluatePharma)
Major Stakeholders	Gilead Sciences (developer), governments, healthcare providers, pharmaceutical distributors
Ownership & Patent Status	Patent holdings expire in key markets by 2030, with some jurisdictions facing patent challenges; patent extensions or secondary patents may prolong exclusivity
Research & Development (R&D) Investment	Gilead invested approximately USD 1.5 billion in COVID-19-related R&D, including remdesivir, with ongoing efforts into analogs and combination therapies
Regulatory Approvals (as of 2023)	Approved for emergency use or full indication in over 50 countries; FDA approved in October 2020, EMA in November 2020

Market Dynamics Shaping the Investment Scenario

1. Regulatory Landscape

Region	Status & Impact	Recent Policy Notes
United States	FDA full approval (October 2020); reimbursement policies integrated into inpatient care	Reimbursement facilitated post-approval, fostering market stability
European Union	Authorized via EMA conditional approval	Pricing negotiations and reimbursement vary by member state
Asia-Pacific	Approvals in Japan, South Korea, Australia	Market expected to grow with COVID-19 variants resurgence

2. Competitive Environment

Key Competitors	Mechanistic Differences	Market Share	Notes
Molnupiravir (Merck)	Oral antiviral, comparable efficacy in mild COVID-19	Growing in outpatient settings	Potential to divert hospital-based therapies
Paxlovid (Pfizer)	Oral, high efficacy, preferred in high-risk patients	Leading market share in outpatient use	Growing competition limiting remdesivir's market expansion
Other Monoclonal Antibodies	Targeted therapy, limited variants coverage	Declining use as variants evolve	Market shrinking for some applications

3. Clinical Trial Data and Efficacy

Key Findings	Implications
Demonstrated reduction in recovery time in hospitalized patients	Maintains role in severe cases
Limited efficacy against emerging variants like Omicron	Market share constraining, leading to demand decline
Reduced mortality demonstrated in some subgroups	Supports ongoing clinical use

4. Pricing and Reimbursement Trends

Pricing Strategy	Region	Impact
Tiered Pricing	Developed vs. developing markets	Influences sales volume and margins
Reimbursement Policies	Public health systems	Critical to market penetration

Financial Trajectory and Forecasts

Projection Parameter	2023-2027 Outlook	Source & Notes
Revenue	From USD 8.2 billion (2022) declining to approx. USD 5 billion by 2025	Industry reports suggest waning demand outside severe cases
Market Share	Decreasing in acute care; stable or modest in COVID-19 residual indications	Competitive pressure from oral antivirals
Profit Margins	Expected to decline marginally due to price pressures and competition	Gilead’s EBITDA margins in remdesivir approximate 45% (2022)
R&D Investment	Sustained for next-generation analogs and combination therapies	USD 200-300 million annually projected

Market Opportunity and Risks

Opportunity Drivers	Risks & Challenges	Implications
Expansion into other viral diseases	Efficacy limitations against new variants	Diversification may mitigate revenue decline
Development of next-generation analogs	Clinical development risk	Potential to extend product lifecycle
Integrated COVID-19 and influenza treatment protocols	Market shifts toward oral antivirals	Possible niche markets for combination therapies
Patent expirations and biosimilar entry	Market penetration erosion	Strategic patent extensions and licensing negotiations critical

---

Comparative Analysis of Remdesivir Investment Potential

Parameter	Remdesivir	Molnupiravir (Merck)	Paxlovid (Pfizer)
Market Stage	Mature, declining	Emerging in outpatient	Rapid growth in outpatient
Efficacy	Proven mainly in hospitalized	Similar efficacy, oral	Superior efficacy with oral dosing
Revenue Outlook (2023-2025)	USD 4–5 billion	USD 2–3 billion	USD 6–8 billion
Intellectual Property	Patent expiry circa 2030	Patent filings pending	Patent protections until at least 2030

FAQs

Q1: Will remdesivir maintain a significant market share post-COVID-19 pandemic?
A: Its role is expected to diminish as oral antivirals and outpatient treatments dominate; however, it will retain niche applications for severe/ hospitalized cases, especially where new variants render oral treatments less effective.

Q2: What are the key regulatory challenges facing remdesivir’s commercialization?
A: Variability in approval status across regions, patent expiries, and evolving treatment recommendations pose regulatory uncertainties.

Q3: How do emerging oral antiviral drugs impact remdesivir’s investment prospects?
A: Oral drugs like molnupiravir and paxlovid offer convenience and higher user acceptance, likely reducing demand for intravenously administered remdesivir.

Q4: Are there opportunities for remdesivir in antiviral combinations?
A: Yes, combination therapies could restore efficacy against variants and broaden clinical applications, representing strategic R&D avenues.

Q5: What is the long-term patent outlook for remdesivir?
A: Patents expire around 2030 in major markets; secondary patents or formulations may extend exclusivity.

---

Key Takeaways

• Market Position: Remdesivir remains a significant COVID-19 treatment in hospital settings, but its market is contracting due to competition and therapy evolution.
• Investment Viability: Short- to medium-term revenues are likely to decline, yet strategic investments in analogs or combination therapies could offer growth.
• Competitive Dynamics: The rise of oral antivirals diminishes remdesivir's footprint, necessitating diversification and innovation.
• Regulatory & Patent Landscape: Expiring patents by 2030 and regional approval variances require vigilant IP management and regulatory strategy.
• Financial Strategy: Focus on R&D for next-generation products, patent extensions, and expanding indications to mitigate revenue decline.

---

References

1. EvaluatePharma. “Global sales data on remdesivir,” 2023.
2. Gilead Sciences. “Veklury (Remdesivir) regulatory filings,” 2022.
3. U.S. Food and Drug Administration. “Remdesivir approval announcement,” October 2020.
4. European Medicines Agency. “EMA conditional approval for remdesivir,” November 2020.
5. Industry Reports. “COVID-19 antiviral market analysis,” 2023.